-
What Is Tumor Mutational Burden?
The Food and Drug Administration approved an immunotherapy drug for tumors with high tumor mutational burden regardless of tumor type. But some medical oncologists say it's not clear the biomarker is valid across all cancer types.
by Anna Azvolinsky
-
Treating Cancer Patients With COVID-19: A New York City Experience
An analysis of cancer patients who were infected with the coronavirus and treated at Memorial Sloan Kettering Cancer Center in New York City suggests certain risk factors may predict more severe COVID-19.
by Anna Azvolinsky
-
Exploring Immunotherapy for Triple Negative Breast Cancer
Following the approval of the first immunotherapy for breast cancer by the U.S. Food and Drug Administration in March 2019, experts at the San Antonio Breast Cancer Symposium discussed avenues for further development.
by Marci A. Landsmann
-
Navigating Hospital Discharge Decisions
Patients with advanced cancer often go to rehabilitation facilities after a hospital stay in hopes of gaining the strength for further treatment, but the majority do not go on to receive additional cancer therapy, a study reports.
by Ashley P. Taylor
-
Immunotherapy in the Elderly
Immune checkpoint inhibitors can be effective treatments for elderly people with some types of advanced cancer, but more information is needed on their risks and benefits in this group.
by Emma Yasinski
-
The Crowded Field of Checkpoint Inhibitors
Drug developers behind currently approved checkpoint inhibitors discuss the pros and cons of competition in the field.
by Kate Yandell
-
What Is Hyper-Progression?
Some researchers believe that immunotherapy occasionally causes cancer to grow faster, a phenomenon dubbed hyper-progression.
by Kate Yandell
-
First Immunotherapy Approved for Breast Cancer
Medical oncologist Leisha A. Emens discusses the significance of the first U.S. Food and Drug Administration approval of an immunotherapy treatment for breast cancer.
by Anna Azvolinsky
-
An Uncommon Partnership
Through the Angiosarcoma Project, researchers are partnering with patients to learn about a rare cancer.
by Ashley P. Taylor
-
Non–Small Cell Lung Cancer Takes Center Stage
A trio of clinical trials at the AACR Annual Meeting spotlight new avenues for non-small cell lung cancer treatment.
by Brad Jones
Cancer Talk
TIL Therapy Amplifies the Immune System’s Attack on Melanoma
The recently approved immunotherapy Amtagvi uses a patient’s own immune cells to destroy advanced melanoma.
by Sandra Gordon
Dealing With Immediate Medical Test ResultsPatients have been entitled to immediate access to medical records and test results for three years as a result of the Cures Act. It has changed how patients and doctors share information.
by Taneia Surles
Empowering Pediatric Cancer PatientsAfter twice being treated for leukemia as a child, Brady Lucas discusses the mental impact of pediatric cancer.
by Suzanne McBride
Light at the End of the Tunnel for ASPS PatientsImmunotherapy has helped some young people with alveolar soft part sarcoma (ASPS), a rare cancer, but there’s more work to be done.
by Kyle Bagenstose